-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $8

Benzinga·11/14/2025 13:02:51
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $10 to $8.